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Severe systemic sepsis in injecting drug users (IDUs).
On 9th July 2001, an informal warning was issued in the United Kingdom that the contaminated batch of
heroin, which was responsible for a number of deaths last year in Scotland, Ireland and various parts of
England, may be in circulation again.  A number of  initial reports from Scotland suggested that this may be
similar to the contaminated batch which was distributed in Dublin last summer and which claimed the lives of
eight heroin users.  There have been three definite cases in Scotland (all three necrotising fasciitis cases of which
one was confirmed at post mortem) and five subsequent probable cases.  A variety of organisms were isolated.
To date, no cases have been identified in Ireland.
The illness is characterized by severe systemic sepsis related to soft tissue inflammation at a subcutaneous/
intramuscular injection site in IDUs.  Variable features including oedema (often extensive), myositis, erythema,
cellulitis, bruised appearance, abscess-like (with little or no pus) blackened/blistered centre, necrosis, necrotising
fasciitis.  Several days after development of the local lesion, there may be a dramatic deterioration, with circulatory
collapse, adult respiratory distress syndrome and/or disseminated intravascular coagulation and a very high
white cell count (>30,000cells/mm3). The patient will often remain mentally
alert until a late stage in the illness.
Any case of local inflammation in a drug user with features consistent
with the description given above and who has died or been sufficiently unwell
to require admission to hospital should be reported to the local Director of
Public Health.
A short fact sheet, containing advice for drug users, has been distributed
through the Directors of Public Health and is available on the NDSC website
(http://www.ndsc.ie). Dr Mary Cronin, NDSC
Outbreak of legionellosis in Spain
An outbreak of legionellosis (Legionnaires’ disease) was reported in the Murcia region, in south east Spain.1 As
of  mid-July, 745 people presented with clinical symptoms, 315 of  which were confirmed as Legionnaires’
disease. This could be the largest outbreak of the disease since it was first recognised in 1976. Most were male
(76%) and about two thirds were over 50 years of age.2 One death was reported in a case in which Legionella
pneumophila serogroup 1 was isolated. Most people affected are Spaniards in the northern neighbourhoods of
Murcia city. No tourists have been identified as cases, to date. A current hypothesis is that cooling towers in four
locations are the most likely sources of infection. A detailed epidemiological and environmental investigation
is under way. The outbreak appears to be over now.
Legionellosis is an acute bacterial disease with two recognised clinical presentations: Legionnaires’ disease
and Pontiac fever. Incubation period is usually 2-10 days. Illness is often mild but may be serious enough to
cause death. Typical early symptoms of  legionellosis include: ‘flu-like illness, muscle aches, headache, tiredness
and dry cough, followed by high fever and chills. Antibiotics can be effective in treating the disease. Water is the
natural habitat for the bacteria that cause legionellosis. Outbreaks are often associated with aerosols arising from
contaminated artificial water sources, such as those found in large air-conditioning units. Human to human
transmission does not occur. Diagnostic serology tests are available in some specialist microbiology laboratories
in Ireland. A rapid urine antigen test is also available.
The Legionnaires’ Disease Subcommittee of  the National Disease Surveillance Centre in Ireland, recently
published the draft document “The Management of Legionnaires’ Disease in Ireland”. The aim of the final
document will be to enhance patient care of those with suspected and
confirmed disease, to improve the notification of these cases and to safeguard
the health of the general public.
1. Cano Portero R and Joseph C. Eurosurveillance Weekly [Online] July 12th 2001
http://www.eurosurv.org/2001/010712.html
2. Navarro C, Garcia-Fulgueiras A, Kool J et al. Eurosurveillance Weekly [Online]
July 19th 2001 http://www.eurosurv.org/2001/010719.html
Figure 1: Scanning electron micrograph of legionella (courtesy of PHIL, CDC)
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Background
Acquired Immunodeficiency Syndrome (AIDS) was first reported
in the United States in June 1981.1 It has since become a major
worldwide pandemic. By the end of 2000, it was estimated that
36.1 million people were living with HIV/AIDS worldwide.2 The
features of the AIDS pandemic differ from country to country and
surveillance systems have been established in order to identify the
magnitude of the epidemic and to estimate trends. AIDS
surveillance was introduced in Ireland in 1985 and in November
2000, the National Disease Surveillance Centre (NDSC) took over
responsibility for AIDS reporting from the Department of Health
and Children (DoHC).
AIDS reporting in Ireland
AIDS reporting in Ireland is a voluntary system. When an individual
develops AIDS, the clinician completes an anonymised AIDS
surveillance form. The form is then sent to the Regional AIDS Co-
ordinator in the relevant Health Board, who in the past, forwarded
this to the National AIDS co-ordinator in the DoHC. Every six
months, a summary of  AIDS surveillance information was
published nationally and was notified to the European Centre for
the Epidemiological Surveillance of  AIDS.  In November 2000,
NDSC assumed responsibility for national AIDS surveillance from
the DoHC. At this time, NDSC received the national AIDS database
and this provided an opportunity to review the epidemiology of
AIDS in Ireland since 1983. The following report is based on AIDS
cases diagnosed from 1983 to December 1999 and reported up to
December 2000. This allows a minimum of one year after AIDS
diagnosis, for cases to be reported.
Epidemiology of AIDS in Ireland, 1983 to 1999
There have been 695 cases of AIDS diagnosed in Ireland between
1983 and 1999. AIDS incidence in Ireland increased rapidly through
the 1980s and early 1990s. AIDS incidence peaked in 1993 and
declined through the mid and late nineties (Figure 1). This decline
is primarily attributed to the early use of highly active antiretroviral
therapy (HAART), which was introduced in Ireland in early 1996.3
This treatment delays the progression to AIDS for persons with
HIV infection. However, it is important to note that the number
of cases in any given year will be subject to revision as further
reports are received. The incidence of AIDS in Ireland is relatively
low when compared with other countries throughout Europe.
The incidence rate (per million population) in Ireland in 1999 was
6.8 while the incidence rates (per million population) in the same
year in various countries in Europe were: Britain: 11.9; Italy: 36.0;
Spain: 77.1; Portugal: 88.3.4
Figure 1: AIDS cases diagnosed in Ireland (1990 to 1999). HIV cases,
1990-2000, for comparison.
While the annual incidence of AIDS has been decreasing since
the mid-1990s, the annual incidence of HIV infection has tripled in
the last five years (Figure 1). There has been a large increase in the
number of new HIV infections in the three commonest
transmission categories, injecting drug users (IDUs), men who have
sex with men (MSM) and heterosexuals. Therefore, it is extremely
important to remember that a review of the epidemiology of AIDS
in Ireland will not provide reliable information on the magnitude
or trends of new HIV infections in Ireland.
Approximately 80% of AIDS cases reported in Ireland were
male, though the percentage of AIDS cases in females has increased
over the past five years. Eighty percent of patients with an AIDS
diagnosis were in the age range 25-44 years (median age 32 years).
Males were older than females at AIDS diagnosis (median age 33
and 29 years, respectively).  IDUs were younger at AIDS diagnosis
than both MSM and heterosexuals with a median age of 30 compared
to 34 and 36 respectively (Table 1).
Table 1: Summary measures of age at diagnosis.
The three major groups affected by AIDS were IDUs (40.6%),
MSM (34.3%) and heterosexuals (13.4%) (Table 2). The number of
AIDS cases in all transmission categories has declined since the mid
1990s and this can be primarily attributed to increased use of
HAART, which has delayed disease progression.  The decline in the
number of cases among MSM and IDUs has been greater than
among persons exposed through heterosexual contact. However, it
is important to note that the rate of AIDS in IDUs is much higher
than the rate in the general population. It has previously been
estimated that Dublin has between 3,000 and 15,000 drug users.5
Taking the upper estimate of  15,000 as denominator, the incidence
rate of AIDS in IDUs in 1999 was 466 per million population
compared to an overall incidence rate of AIDS of 6.8 per million  in
the general population.
Table 2: AIDS cases by transmission category.
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Seventy eight percent of AIDS diagnoses occurred in patients who
were resident in the Eastern Regional Health Authority (ERHA) area
and fifteen percent were resident outside the ERHA area. In the
remaining 7% of cases, the area of residence was not identified. Due
to small numbers and in order to maintain anonymity, cases are
classified as ERHA and non-ERHA and are not detailed further. In
1999 the incidence of AIDS (per million population) in the ERHA
area was 13.9 compared to 3.0 in non-ERHA areas. In particular,
almost all AIDS cases (98%) among IDUs occurred in the ERHA
area.
 Of the 695 cases of AIDS reported between 1983 and 1999, 357
(51%) have died. Since 1995, the annual number of deaths among
persons with AIDS has decreased (Figure 2). The mortality rate for
AIDS cases in Ireland has dropped from 13.8 deaths per million
population in 1995 to 4.7 deaths per million population in 1999. This
decrease in AIDS related deaths again reflects the improved survival
among persons with AIDS due to improvements in medical care and
the effect of  HAART.3 The use of  antimicrobial prophylaxis to delay
or prevent the development of a number of opportunistic infections
has also contributed to improved survival.6
Figure 2: AIDS related deaths in Ireland, 1985 to 1999.
The Future
AIDS surveillance in Ireland is a voluntary reporting system which
has been in place since 1985. It has proven extremely valuable for a
number of  reasons. AIDS surveillance data is essential in order to
assess the magnitude of the epidemic in Ireland.  In the past, it has
allowed us to identify the burden on healthcare services and examine
trends in access to care and treatment outcomes. However, it is clear
that monitoring trends in the AIDS epidemic alone no longer reliably
reflects trends in HIV infection. It is therefore extremely important
that all diagnosed HIV infections are reported so that the appropriate
prevention strategies and services can be put in place.
HIV case-based reporting
Prior to July 2001, the National Virus Reference Laboratory provided
information on newly diagnosed HIV infections. This information
was published by the DoHC and more recently by the NDSC on a
twice-yearly basis. Following a recommendation from the National
AIDS Strategy Committee, HIV case-based reporting was introduced
in Ireland on July 1st 2001.7 The new system will collect demographic
and risk transmission information on individual HIV positive cases.
All cases of AIDS will continue to be reported through this new
system. The Director of Public Health in each health board will collect
this information and report, nationally, to NDSC. A new joint HIV/
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AIDS surveillance form has been designed and will replace the
current AIDS surveillance report form. The aim of  this new system
is to provide reliable information about the incidence, demographics
and future trends of HIV infection. In time, it will be possible to
link newly diagnosed AIDS cases to previously identified HIV
positive cases, thus enabling progression of the disease from HIV
infection to AIDS to be monitored.
We anticipate that an evaluation of  this new system will be
carried out in 2002. A report will be compiled in association with
the HIV Case-based Reporting Group and Dr Colm Bergin, St
James’s Hospital (on behalf  of  the consultants in infectious
disease/genito-urinary medicine).
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Key Points:
• A total of 695 cases of AIDS were diagnosed in
Ireland from 1983 to 1999 and there has been a
decrease in the annual incidence of AIDS since the
mid-1990s
• Despite the decrease in the number of AIDS
cases in Ireland, the number of new HIV infections
tripled from 1994 to 1999.
• The majority of affected people were in the age
range 25-44 years. Eighty percent of cases were male,
and males were older at diagnosis then females
• The major groups affected by AIDS in Ireland
were injecting drug users, men who have sex with men
and heterosexuals
• Seventy eight percent of AIDS cases were
resident in the ERHA area
• Fifty one percent of AIDS cases in Ireland have
died
• A new improved system for monitoring trends in
HIV infection was introduced in Ireland in July 2001.
This system aims to ensure the collection of accurate
and complete epidemiological data on the trends of
the HIV epidemic in Ireland.
The views expressed in this publication are those of the individual contributors and not necessarily those of the NDSC. The NDSC have made all reasonable efforts to ensure
that all information in the publication is accurate at time of publication, however in no event shall the NDSC be liable for any loss, injury or incidental, special, indirect or
consequential damage or defamation arising out of, or in connection with, this publication or other material derived from, or referred to in, the publication.
Strains are allocated to months based on the date of receipt of the
isolate from the referring laboratory. These figures are provisional as
work may not be finished on particular strains at the time of publica-
tion. Data are provided courtesy of Prof Martin Cormican and Dr
Geraldine Corbett-Feeney, INSRL.
draoBhtlaeH E M WM EN WN ES S W latoT
muirumihpyT.S 7 0 5 2 1 1 0 2 81
siditiretnE.S 31 1 0 1 0 3 5 4 72
yenederB.S 0 0 0 0 0 1 0 0 1
nilbuD.S 1 0 0 0 0 0 0 0 1
radaH.S 1 0 0 0 0 0 1 1 3
grebledieH.S 0 2 0 0 0 0 0 0 2
nehcsramhtO.S 1 0 0 0 0 0 0 0 1
latoT 32 3 5 3 1 5 6 7 35
Salmonella Monthly Report (June 2001):
Annual Conference on
epidemiology and control of
communicable diseases and
environmental hazards
The annual conference on epidemiology and control of communicable
diseases and environmental hazards takes place from Monday 5th to
Wednesday 7th November 2001, at Dublin Castle, Dublin.  This is the
first time that this prestigious international conference, involving
England, Wales, Scotland, Northern Ireland and Ireland will be held
outside London.  It is being organised jointly by the five surveillance
institutes and there are five main themes for the conference:
antimicrobial resistance and hospital acquired infection; immunisation;
social inequalities and infectious disease; environmental hazards; and
control and prevention policies: evidence and effectiveness. The
conference will address important public health issues that have arisen
in the past year and will provide fresh perspectives on established areas
of disease prevention and control.  Short papers on recent outbreaks
and surveillance initiatives will also be presented. Abstracts are now
invited for papers and posters on these themes. The conference is
aimed primarily at those working in public health who have
responsibility for infectious diseases and environmental health, but
will also be of interest to consultants in infectious diseases,
microbiologists, infection control nursing professionals and
environmental health officers.
For further information on the conference and details on submission
of  abstracts, please go to www.ndsc.ie or contact Dr Derval Igoe at
the National Disease Surveillance Centre.
The National Disease Surveillance Centre (NDSC) has worked in
collaboration with the National Virus Reference Laboratory (NVRL)
and the Irish College of General Practitioners (ICGP) for the first year
of  the influenza surveillance scheme.
Sentinel General Practitioners (GPs) reported consultations for
influenza-like illness (ILI) from week 40, 2000 to week 20 (May 20th),
2001 (Figure 1). Peak incidence occurred during week 8 and coincided
with an increase in influenza B. The consultation rate for week 8 was
121 per 100,000 population. A second smaller peak occurred during
week 11, with a consultation rate of 109 per 100,000. From week 13,
the consultation rate decreased steadily until week 20. The peak age
specific consultation rate was in the 15-44 year age group. Fifty-one
percent of consultations for ILI were male and 49% were female.
The NVRL received 329 swabs from sentinel GPs; 42.6% were
positive for influenza virus. The highest number of positive samples
occurred during the period of  peak clinical activity. Influenza A accounted
for 39.3% of positive swabs; 35% were influenza A (H1N1), 2.9% were
influenza A (H3N2), and 1.4% were unsubtyped influenza A. Influenza
B accounted for 60.7% of the positive swabs. Influenza A was the
predominant strain from week 40, 2000 until week 6, 2001, after which
influenza B predominated. No swabs were positive for influenza virus
after week 15 (Figure 2). The highest number of positive swabs was in
the 15-44 year age group. Of  the 140 positive swabs, 52.1% were male,
47.1% were female, and 0.7% was of unknown sex. The 2000/2001
influenza vaccine protected against all virus isolates antigenically
characterised by the WHO laboratory in London. Further improvements
to the influenza surveillance scheme, next season, will include data on
school absenteeism, hospital admission rates, levels of illness in nursing
homes and an increase in the number of sentinel GPs.
Ms L Domegan, Dr N Mullins, Dr D O’Flanagan, NDSC; Dr D
Nolan, Dr P McCormick, ICGP, & Dr S Coughlan, Mr S Dooley, Mr
P Quinn, NVRL.
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Influenza Surveillance 2000/2001 Update
Figure 1: GP consultation rate for ILI per 100,000 population by report
week
Congratulations to Eurosurveillance!
The National Library of Medicine has selected Eurosurveillance
(monthly) to be indexed and included in Index Medicus and
MEDLINE on the MEDLARS system. Eurosurveillance was established
in 1996 and aims to increase awareness of communicable disease
incidence trends and outbreaks, to foster links between those working
in the prevention and control of communicable diseases, and to
promote better working practices.
Eurosurveillance is available on the internet at:
http://www.eurosurv.org
 For further information, the Irish representative on the editorial
board of Eurosurveillance is Dr Lelia Thornton: thornton@ehbph.iol.ie
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Figure 2: Number of positive swabs by flu type and % positive of total swabs
by week
